PLR与恶性肿瘤同步放化疗预后的研究进展

doi:10.11904/j.issn.1002-3070.2020.03.016

摘要/Abstract

摘要： 目前,对于放疗敏感且失去手术机会的癌症患者而言,同步放化疗是主要的治疗手段,合理的放疗疗效监测指标,可以在很大程度上为癌症患者预后的评估提供参考价值。血小板与淋巴细胞比值(Platelet to lymphocyte ratio,PLR)是评价机体炎症反应的指标之一,与单独评价淋巴细胞和血小板计数相比,可以更准确和敏感地反映患者的炎症状态。已有文献报导PLR与恶性肿瘤放化疗的相关性,且在预后评估方面受到了越来越多的关注。本文将对PLR在恶性肿瘤放化疗预后的研究进展进行阐述。

关键词: PLR, 同步放化疗, 预后

Abstract: At present,for cancer patients who are sensitive to radiotherapy and have no chance of surgery,concurrent chemoradiotherapy is the main treatment.Reasonable radiotherapy efficacy monitoring indicators can provide a reference value for the evaluation of prognosis for cancer patients.Platelet to lymphocyte ratio(PLR)is one of indicators for evaluating body′s inflammatory response.Compared with the lymphocyte and platelet counts alone,PLR can reflect the inflammatory state of patients more accurately and sensitively.The literature has reported the correlation between PLR and malignant tumor radiotherapy and chemotherapy,and has received more and more attention in the evaluation of patient prognosis.This article will review the research progress of PLR in the prognosis of malignant tumor radiotherapy and chemotherapy.

Key words: PLR, Concurrent chemoradiotherapy, Prognosis

中图分类号:

王棹, 冯越, 邢丽楠, 张云艳. PLR与恶性肿瘤同步放化疗预后的研究进展[J]. 实用肿瘤学杂志, 2020, 34(3): 271-275.

WANG Zhao,FENG Yue,XING Linan,ZHANG Yunyan. Advances in the prognosis of PLR and malignant tumors with concurrent chemoradiotherapy[J]. Journal of Practical Oncology, 2020, 34(3): 271-275.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2020.03.016

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2020/V34/I3/271

参考文献

1 Wu CC,Li SH,Lu HI,et al.Inflammation-based prognostic scores predict the prognosis of locally advanced cervical esophageal squamous cell carcinoma patients receiving curative concurrent chemoradiotherapy:a propensity score-matched analysis[J].Peer J,2018,6:e5655.
2 Zou J,Yang Y,Yang Y,et al.Polydatin suppresses proliferation and metastasis of non-small cell lung cancer cells by inhibiting NLRP3 inflammasome activation via NF-kappaB pathway[J].Biomed Pharmacother,2018,108:130-136.
3 Unal D,Eroglu C,Kurtul N,et al.Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis?[J].Asian Pac J Cancer Prev,2013,14(9):5237-5242.
4 Masjedi A,Hashemi V,Hojjat-Farsangi M,et al.The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer[J].Biomed Pharmacother,2018,108:1415-1424.
5 Mehrazin R,Uzzo RG,Kutikov A,et al.Lymphopenia is an independent predictor of inferior outcome in papillary renal cell carcinoma[J].Urol Oncol,2015,33(9):388.319-325.
6 Wang YH,Deng SJ,Yang YD,et al.The pretreatment thrombocytosis may predict prognosis of patients with colorectal cancer:a systematic review and meta-analysis[J].Biomark Med,2017,11(2):195-210.
7 Zhang XJ,Liu YG,Shi XJ,et al.The prognostic role of neutrophils to lymphocytes ratio and platelet count in gastric cancer:a meta-analysis[J].Int J Surg,2015,21:84-91.
8 Guo J,Fang J,Huang X,et al.Prognostic role of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in prostate cancer:a meta-analysis of results from multivariate analysis[J].Int J Surg,2018,60:216-223.
9 Li B,Zhou P,Liu Y,et al.Platelet-to-lymphocyte ratio in advanced cancer:review and meta-analysis[J].Clin Chim Acta,2018,483:48-56.
10 Ma JY,Ke LC,Liu Q.The pretreatment platelet-to-lymphocyte ratio predicts clinical outcomes in patients with cervical cancer:a meta-analysis[J].Medicine(Baltimore),2018,97(43):e12897.
11 Takenaka Y,Oya R,Kitamiura T,et al.Platelet count and platelet-lymphocyte ratio as prognostic markers for head and neck squamous cell carcinoma:meta-analysis[J].Head Neck,2018,40(12):2714-2723.
12 Yang HX,Zhang XM,Hao ZP.The diagnostic accuracy of a real-time optoelectronic device in cervical cancer screening:a PRISMA-compliant systematic review and meta-analysis[J].Medicine(Baltimore),2018,97(29):e11439.
13 Smith RA,Bosonnet L,Raraty M,et al.Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma[J].Am J Surg,2009,197(4):466-472.
14 Rao AK,Rao DA.Platelets signal and tumors take off[J].Blood,2012,120(24):4667-4668.
15 Wu T,Li Y,Lu J,et al.Increased MMP-21 expression is associated with poor overall survival of patients with gastric cancer[J].Med Oncol,2013,30(1):323.
16 Dunn GP,Bruce AT,Ikeda H,et al.Cancer immunoediting:from immunosurveillance to tumor escape[J].Nat Immunol,2002,3(11):991-998.
17 Mantovani A,Allavena P,Sica A,et al.Cancer-related inflammation[J].Nature,2008,454(7203):436-444.
18 Stotz M,Gerger A,Eisner F,et al.Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer[J].Br J Cancer,2013,109(2):416-421.
19 Zhang J,Huang SH,Li H,et al.Preoperative lymphocyte count is a favorable prognostic factor of disease-free survival in non-small-cell lung cancer[J].Med Oncol,2013,30(1):352.
20 Siegel RL,Miller KD,Jemal A.Cancer statistics,2018[J].CA Cancer J Clin,2018,68(1):7-30.
21 Onal C,Guler OC,Yildirim BA.Prognostic use of pretreatment hematologic parameters in patients receiving definitive chemoradiotherapy for cervical cancer[J].Int J Gynecol Cancer,2016,26(6):1169-1175.
22 Lee JW,Jeon S,Mun ST,et al.Prognostic value of fluorine-18 fluorodeoxyglucose uptake of bone marrow on positron emission tomography/computed tomography for prediction of disease progression in cervical cancer[J].Int J Gynecol Cancer,2017,27(4):776-783.
23 Holub K,Biete A.Impact of systemic inflammation biomarkers on the survival outcomes of cervical cancer patients[J].Clin Transl Oncol,2019,21(7):836-844.
24 Haraga J,Nakamura K,Omichi C,et al.Pretreatment prognostic nutritional index is a significant predictor of prognosis in patients with cervical cancer treated with concurrent chemoradiotherapy[J].Mol Clin Oncol,2016,5(5):567-574.
25 Bond-Smith G,Banga N,Hammond TM,et al.Pancreatic adenocarcinoma[J].BMJ,2012,344:e2476.
26 Konstantinidis IT,Warshaw AL,Allen JN,et al.Pancreatic ductal adenocarcinoma:is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection?[J].Ann Surg,2013,257(4):731-736.
27 Lee BM,Chung SY,Chang JS,et al.The neutrophil-lymphocyte ratio and platelet-lymphocyte ratio are prognostic factors in patients with locally advanced pancreatic cancer treated with chemoradiotherapy[J].Gut Liver,2018,12(3):342-352.
28 刘建辉,罗妍,陈晓,等.放疗前中性粒细胞/淋巴细胞血小板/淋巴细胞预后营养指数及CA19-9与胰腺腺癌放疗后预后关系的分析[J].中国肿瘤临床,2017,44(6):289-293.
29 Dongwook O,Jung-Soo P,Kuan SD.Prognostic roles of inflammatory markers in pancreatic cancer:comparison between the neutrophil-to-Lymphocyte ratio and platelet-to-lymphocyte ratio[J].Gastroenterol Res Pract,2018,2018:9745601.
30 Zeng H,Zheng R,Guo Y,et al.Cancer survival in China,2003-2005:a population-based study[J].Int J Cancer,2015,136(8):1921-1930.
31 Miao C,Zhu S,Pan H,et al.Combined neutrophil-platelet score and hemoglobin level predict survival in esophageal squamous cell carcinoma patients treated with chemoradiotherapy[J].Oncotarget,2017,8(50):87971-87979.
32 Zhu S,Miao CW,Wang ZT,et al.Sensitivity value of hematological markers in patients receiving chemoradiotherapy for esophageal squamous cell carcinoma[J].Onco Targets Ther,2016,9:6187-6193.
33 Tang Y,Li G,Wu S,et al.Programmed death ligand 1 expression in esophageal cancer following definitive chemoradiotherapy:prognostic significance and association with inflammatory biomarkers[J].Oncol Lett,2018,15(4):4988-4996.
34 Vansteenkiste J,De Ruysscher D,Eberhardt WE,et al.Early and locally advanced non-small-cell lung cancer(NSCLC):ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2013,24(Suppl 6):89-98.
35 NSCLC Meta-analysis Collaborative Group.Preoperative chemotherapy for non-small-cell lung cancer:a systematic review and meta-analysis of individual participant data[J].Lancet,2014,383(9928):1561-1571.
36 Stinchcombe TE,Zhang Y,Vokes EE,et al.Pooled analysis of individual patient data on concurrent chemoradiotherapy for stage III non-small-cell lung cancer in elderly patients compared with younger patients who participated in US National Cancer Institute Cooperative Group Studies[J].J Clin Oncol,2017,35(25):2885-2892.
37 Antoni D,Mornex F.Chemoradiotherapy of locally advanced nonsmall cell lung cancer:state of the art and perspectives[J].Curr Opin Oncol,2016,28(2):104-109.
38 Pless M,Stupp R,Ris HB,et al.Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer:a phase 3 randomised trial[J].Lancet,2015,386(9998):1049-1056.
39 Tong YS,Tan J,Zhou XL,et al.Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer[J].J Transl Med,2017,15(1):221.
40 Cannon NA,Meyer J,Iyengar P,et al.Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer[J].J Thorac Oncol,2015,10(2):280-285.
41 Shaverdian N,Veruttipong D,Wang J,et al.Pretreatment immune parameters predict for overall survival and toxicity in early-stage non-small-cell lung cancer patients treated with stereotactic body radiation therapy[J].Clin Lung Cancer,2016,17(1):39-46.
42 Kano S,Homma A,Hatakeyama H,et al.Pretreatment lymphocyte-to-monocyte ratio as an independent prognostic factor for head and neck cancer[J].Head Neck,2017,39(2):247-253.
43 Sun W,Zhang L,Luo M,et al.Pretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma:neutrophil-lymphocyte ratio and platelet-lymphocyte ratio[J].Head Neck,2016,38(Suppl 1):1332-1340.
44 Ye L,Oei RW,Kong F,et al.Prognostic values of hematological biomarkers in nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy[J].Eur Arch Otorhinolaryngol,2018,275(5):1309-1317.

[1]	谢贤鑫, 韦军, 邱佳鑫, 王聪, 姜大庆. 乳腺癌新辅助化疗残余肿瘤组织病理信息与预后分析[J]. 实用肿瘤学杂志, 2020, 34(3): 225-231.
[2]	苏文佳, 王树叶. 滤泡性淋巴瘤的预后分层和治疗进展[J]. 实用肿瘤学杂志, 2020, 34(2): 189-192.
[3]	廖代祥, 郑博, 张彦斌, 于军辉. RRBP1与RABEX-5蛋白在结直肠癌组织中的表达及与临床病理特征和预后的关系[J]. 实用肿瘤学杂志, 2020, 34(1): 43-48.
[4]	刘耿淳, 申良方. 血清长链非编码RNA MALAT1和AFAP1-AS1与鼻咽癌临床病理特征和预后的关系[J]. 实用肿瘤学杂志, 2019, 33(6): 513-518.
[5]	范晋海, 蒋玉梅, 张静, 白晓静. MAP1A在膀胱癌组织中的表达及其与临床病理特征的关系[J]. 实用肿瘤学杂志, 2019, 33(6): 525-530.
[6]	刘四卫, 崔玥, 孙元元, 胡晶, 张文睿, 曹孟儒. FOXD3在肺癌细胞中的作用[J]. 实用肿瘤学杂志, 2019, 33(5): 390-396.
[7]	夏天一, 张博淼, 姚克非, 崔滨滨. PTPN9表达水平与结直肠癌的临床关系研究[J]. 实用肿瘤学杂志, 2019, 33(5): 415-419.
[8]	徐亭, 严斐斐, 张纯慧, 张艳桥. 胃癌骨转移患者临床病理与预后分析[J]. 实用肿瘤学杂志, 2019, 33(5): 436-441.
[9]	李思维 , 庞达. 长链非编码RNA(lncRNA)在癌症中的作用[J]. 实用肿瘤学杂志, 2019, 33(5): 471-475.
[10]	曲雁飞, 刘超, 王勃军, 方琳, 张艳桥. CSN6基因在肝细胞癌组织中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(4): 328-333.
[11]	刘金涛, 高玲, 周会会. MAGEA4和EB1蛋白在肺癌组织中的表达及其与临床病理特征及预后的相关性分析[J]. 实用肿瘤学杂志, 2019, 33(4): 334-339.
[12]	王晓雅,肖斌,廖扬,唐荣芝,孙朝晖,李林海. CXCR家族蛋白在不同乳腺癌亚型中的表达及临床预后分析[J]. 实用肿瘤学杂志, 2019, 33(3): 206-210.
[13]	冯越,邢丽楠,王棹,张云艳. NLR与肿瘤同步放化疗预后的相关性研究[J]. 实用肿瘤学杂志, 2019, 33(3): 284-288.
[14]	白晓斌, 霍龙伟, 谢万福, 徐高峰, 王茂德. Chk1在胶质母细胞瘤中的表达及其与肿瘤生物学行为和预后生存的关联性[J]. 实用肿瘤学杂志, 2019, 33(2): 122-127.
[15]	石小康, 丁佑铭, 汪斌, 余斌, 徐雨. UBE2T在原发性肝癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(2): 128-133.